Albumin is emerging as one of the most attractive drug carriers for the targeted delivery of therapeutic peptides and drugs. Herein, we developed a label-free MRI approach for monitoring albumin-based drug delivery systems by directly utilizing the inherent CEST signal of albumin. Our in vitro study showed that both human serum albumin (HSA) and albumin-based nanoparticle Nab-paclitaxel (Abraxane) could generate a strong CEST signal at ~2 ppm. Using this inherent CEST signal, we successfully demonstrated the label-free CEST MRI detection of the tumor uptake and distribution HSA and Nab-paclitaxel in a xenograft mouse model.
This abstract and the presentation materials are available to members only; a login is required.